These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 30367089

  • 21. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
    Hou HA, Kuo YY, Tang JL, Chou WC, Yao M, Lai YJ, Lin CC, Chen CY, Liu CY, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Liu CW, Huang SY, Ko BS, Wu SJ, Tsay W, Chen YC, Tien HF.
    Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
    [Abstract] [Full Text] [Related]

  • 22. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
    Chou AH, Chen YL, Hu SH, Chang YM, Wang HL.
    Brain Res; 2014 Oct 02; 1583():220-9. PubMed ID: 25139423
    [Abstract] [Full Text] [Related]

  • 23. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
    Chou AH, Chen SY, Yeh TH, Weng YH, Wang HL.
    Neurobiol Dis; 2011 Feb 02; 41(2):481-8. PubMed ID: 21047555
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia.
    D'Altri T, Wilhelmson AS, Schuster MB, Wenzel A, Kalvisa A, Pundhir S, Meldgaard Hansen A, Porse BT.
    Haematologica; 2021 Apr 01; 106(4):1000-1007. PubMed ID: 32381577
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D, Marcucci G.
    J Pharmacol Exp Ther; 2007 Jun 01; 321(3):953-60. PubMed ID: 17389244
    [Abstract] [Full Text] [Related]

  • 29. Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.
    Tamura M, Yonezawa T, Liu X, Asada S, Hayashi Y, Fukuyama T, Tanaka Y, Kitamura T, Goyama S.
    Sci Rep; 2019 Jun 03; 9(1):8171. PubMed ID: 31160638
    [Abstract] [Full Text] [Related]

  • 30. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
    Choi HW, Kim HR, Baek HJ, Kook H, Cho D, Shin JH, Suh SP, Ryang DW, Shin MG.
    Ann Lab Med; 2015 Jan 03; 35(1):118-22. PubMed ID: 25553291
    [Abstract] [Full Text] [Related]

  • 31. [Role of ASXL1 mutations in hematological disorders].
    Uni M.
    Rinsho Ketsueki; 2019 Jan 03; 60(6):680-690. PubMed ID: 31281161
    [Abstract] [Full Text] [Related]

  • 32. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.
    Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Knudson RA, Ketterling RP, Tefferi A, Solary E.
    Leukemia; 2014 Nov 03; 28(11):2206-12. PubMed ID: 24695057
    [Abstract] [Full Text] [Related]

  • 33. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
    Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, Birnbaum D, Mozziconacci MJ.
    Am J Hematol; 2012 Jul 03; 87(7):659-62. PubMed ID: 22535592
    [Abstract] [Full Text] [Related]

  • 34. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
    Zhang P, He F, Bai J, Yamamoto S, Chen S, Zhang L, Sheng M, Zhang L, Guo Y, Man N, Yang H, Wang S, Cheng T, Nimer SD, Zhou Y, Xu M, Wang QF, Yang FC.
    J Clin Invest; 2018 Dec 03; 128(12):5383-5398. PubMed ID: 30226831
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.
    Inoue D, Fujino T, Sheridan P, Zhang YZ, Nagase R, Horikawa S, Li Z, Matsui H, Kanai A, Saika M, Yamaguchi R, Kozuka-Hata H, Kawabata KC, Yokoyama A, Goyama S, Inaba T, Imoto S, Miyano S, Xu M, Yang FC, Oyama M, Kitamura T.
    Leukemia; 2018 Jun 03; 32(6):1327-1337. PubMed ID: 29556021
    [Abstract] [Full Text] [Related]

  • 38. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
    Qi H, Ratnam M.
    Cancer Res; 2006 Jun 01; 66(11):5875-82. PubMed ID: 16740727
    [Abstract] [Full Text] [Related]

  • 39. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
    Zhang Y, Fatima N, Dufau ML.
    Mol Cell Biol; 2005 Sep 01; 25(18):7929-39. PubMed ID: 16135786
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.